No clinical trials of BET inhibitors in COVID-19 have been initiated at the time of this publication, but several compounds have been advanced to the clinic for other indications such as cancer, including OTX015/MK-8628 highlighted in our study, and possess the potential to be quickly repurposed for COVID-19 (31). This evidence concerns the gene DNER and COVID-19.